TP53-mutated AML is also enriched for the tumor inflammation signature (TIS), as well as characterized by the upregulation of immune checkpoints such as PD-L1, TIGIT, and LAG3 and markers of immune senescence [77]. The gene discussed is CD274; the disease is acute myeloid leukemia.